Search by Drug Name or NDC
NDC 43538-0550-60 Loprox 7.7 mg/mL Details
Loprox 7.7 mg/mL
Loprox is a TOPICAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Medimetriks Pharmaceuticals, Inc.. The primary component is CICLOPIROX OLAMINE.
MedlinePlus Drug Summary
Ciclopirox topical solution is used along with regular nail trimming to treat fungal infections of the fingernails and toenails (an infection that may cause nail discoloration, splitting and pain). Ciclopirox is in a class of medications called antifungals. It works by stopping the growth of nail fungus.
Related Packages: 43538-0550-60Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ciclopirox Topical
Product Information
| NDC | 43538-0550 |
|---|---|
| Product ID | 43538-550_0efc4273-be47-4751-98f8-626f3fb85754 |
| Associated GPIs | 90150030101810 |
| GCN Sequence Number | 040298 |
| GCN Sequence Number Description | ciclopirox olamine SUSPENSION 0.77 % TOPICAL |
| HIC3 | Q5F |
| HIC3 Description | TOPICAL ANTIFUNGALS |
| GCN | 95353 |
| HICL Sequence Number | 003203 |
| HICL Sequence Number Description | CICLOPIROX OLAMINE |
| Brand/Generic | Brand |
| Proprietary Name | Loprox |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ciclopirox olamine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION |
| Route | TOPICAL |
| Active Ingredient Strength | 7.7 |
| Active Ingredient Units | mg/mL |
| Substance Name | CICLOPIROX OLAMINE |
| Labeler Name | Medimetriks Pharmaceuticals, Inc. |
| Pharmaceutical Class | Decreased DNA Replication [PE], Decreased Protein Synthesis [PE], Decreased RNA Replication [PE], Protein Synthesis Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA019824 |
| Listing Certified Through | 2023-12-31 |
Package
Package Images
NDC 43538-0550-60 (43538055060)
| NDC Package Code | 43538-550-60 |
|---|---|
| Billing NDC | 43538055060 |
| Package | 1 BOTTLE in 1 CARTON (43538-550-60) / 60 mL in 1 BOTTLE |
| Marketing Start Date | 2016-10-14 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL befa91b7-ea2b-4fbb-9e4c-45993bfd7c18 Details
DESCRIPTION
LOPROX® (ciclopirox) Topical Suspension, 0.77% is for topical use.
Each gram of LOPROX® Topical Suspension contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible suspension base consisting of purified water USP, cocamide DEA, octyldodecanol NF, mineral oil USP, stearyl alcohol NF, cetyl alcohol NF, polysorbate 60 NF, myristyl alcohol NF, lactic acid USP, sorbitan monostearate NF, and benzyl alcohol NF (1%) as preservative.
LOPROX® Topical Suspension contains a synthetic, broad spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt.
The CAS Registry Number is 41621-49-2.
LOPROX® Topical Suspension has a pH of 7.
The chemical structure is:
CLINICAL PHARMACOLOGY
Mechanism of Action
Ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (Fe3+ or Al3+), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.
Pharmacokinetics
Pharmacokinetic studies in men with radiolabeled ciclopirox solution in polyethylene glycol 400 showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm2 on the back followed by occlusion for 6 hours.
The biological half life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible. Autoradiographic studies with human cadaver skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.
In vitro penetration studies in frozen or fresh excised human cadaver and pig skin indicated that the penetration of LOPROX® Topical Suspension is equivalent to that of LOPROX® (ciclopirox) Cream, 0.77%. Therapeutic equivalence of cream and suspension formulations also was indicated by studies of experimentally induced guinea pig and human trichophytosis.
INDICATIONS AND USAGE
LOPROX® Topical Suspension is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; ; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur.
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
If a reaction suggesting sensitivity or chemical irritation should occur with the use of LOPROX® Topical Suspension, treatment should be discontinued and appropriate therapy instituted.
Information for Patients
The patient should be told to:
- Use the medication for the full treatment time even though signs/symptoms may have improved and notify the physician if there is no improvement after four weeks.
- Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, oozing) indicative of possible sensitization.
- Avoid the use of occlusive wrappings or dressings
Carcinogenesis, Mutagenesis, Impairment of Fertility
A 104-week dermal carcinogenicity study in mice was conducted with ciclopirox cream applied at doses up to 1.93% (100 mg/kg/day or 300 mg/m2/day). No increase in drug related neoplasms was noted when compared to control.
The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5000 mg/kg body weight.
A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.2 times the maximum recommended human dose based on body surface area comparisons).
Pregnancy
Teratogenic Effects
Pregnancy Category B
There are no adequate or well-controlled studies in pregnant women. Therefore, LOPROX® Topical Suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 11, 37, 51 and 24 times the maximum recommended human dose based on body surface area comparisons, respectively).
Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 27 and 49 times the maximum recommended human dose based on body surface area comparisons, respectively).
ADVERSE REACTIONS
In the controlled clinical trial with 89 patients using LOPROX® Topical Suspension and 89 patients using the vehicle, the incidence of adverse reactions was low. Those considered possibly related to treatment or occurring in more than one patient were pruritus, which occurred in two patients using ciclopirox suspension and one patient using the suspension vehicle, and burning, which occurred in one patient using ciclopirox suspension.
DOSAGE AND ADMINISTRATION
Gently massage LOPROX® Topical Suspension into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with LOPROX® Topical Suspension, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.
HOW SUPPLIED
SPL UNCLASSIFIED SECTION
PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton
NDC 43538-550-60
For Topical Use Only
Not for use in eyes
60 mL
LOPROX®
(ciclopirox)
Topical
Suspension,
0.77%
Rx Only
MEDIMETRIKS
PHARMACEUTICALS, INC.
PRINCIPAL DISPLAY PANEL - Kit Carton
NDC 43538-551-60
For Topical Use Only
Not for use in eyes
60mL
Rx Only
LOPROX®
(ciclopirox)
Topical
Suspension,
0.77%
KIT
KIT CONTAINS:
- 1 -
- LOPROX® (ciclopirox) Topical Suspension, 0.77%
60 mL Bottle - 1 -
- Rehyla® Hair + Body Cleanser
Net wt. 16 oz. (454 g) Bottle
MEDIMETRIKS
PHARMACEUTICALS, INC.
INGREDIENTS AND APPEARANCE
| LOPROX
ciclopirox olamine suspension |
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
| LOPROX
ciclopirox olamine kit |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Labeler - Medimetriks Pharmaceuticals, Inc. (019903816) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Teligent | 011036910 | MANUFACTURE(43538-550, 43538-551) , PACK(43538-550, 43538-551) | |